Joel Neal, MD, PhD
Dr. Joel Neal is a thoracic oncologist who treats patients with lung cancer, malignant pleural mesothelioma, and other thoracic malignancies at the Stanford Cancer Institute in Palo Alto, California. His treatment relies on the findings of his clinical trials, which focus on overcoming acquired resistance to targeted therapies, understanding and improving the efficacy of immunotherapy and applying circulating tumor DNA technology.[1]
Education and Career
Dr. Neal attended medical school at Northwestern University in Chicago, Illinois, where he earned both his medical degree and a doctoral degree in Tumor Cell Biology. He then pursued a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts.[1]
He is a member of the International Association for the Study of Lung Cancer (IASLC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at several American Society of Clinical Oncology (ASCO) annual meetings. Dr. Neal also leads the Stanford Thoracic Clinical Research Group and is the IT Medical Director of the Stanford Cancer Center.[1]
Research
Dr. Neal’s research focus is on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and malignant pleural mesothelioma. He has published many articles about thoracic oncology in esteemed medical publications including Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology.[1]
His recent publications include:
- Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., … Han, S. S. (2023). Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. JAMA Network Open, 6(11), e2343278. - Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. - Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.
Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., … Plevritis, S. K. (2023). Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports, 13(1), 21781. - Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., … Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer. - Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine. - Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou, S.-H. I., Prawitz, T., Lin, H. M., Hong, J.-L. L., Tan, M., Proskorovsky, I., … Neal, J. W. (2023). Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Clinical Lung Cancer. - Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine, 25(12), 715–735.
Open clinical trials include:[1]
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer »
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer »
- A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer »
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations »
- Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors »
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) »
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) »
- A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer »
